vs

Side-by-side financial comparison of NEKTAR THERAPEUTICS (NKTR) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $11.5M, roughly 1.9× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -25.3%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-65.0M). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs 0.4%).

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

Roper Technologies, Inc. is a holding company that owns companies in the technology sector.

NKTR vs TACT — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.9× larger
NKTR
$21.8M
$11.5M
TACT
Growing faster (revenue YoY)
TACT
TACT
+37.2% gap
TACT
11.9%
-25.3%
NKTR
More free cash flow
TACT
TACT
$65.6M more FCF
TACT
$589.0K
$-65.0M
NKTR
Faster 2-yr revenue CAGR
TACT
TACT
Annualised
TACT
3.5%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NKTR
NKTR
TACT
TACT
Revenue
$21.8M
$11.5M
Net Profit
$-36.1M
Gross Margin
47.6%
Operating Margin
-126.9%
-10.1%
Net Margin
-165.4%
Revenue YoY
-25.3%
11.9%
Net Profit YoY
-596.9%
EPS (diluted)
$-4.67
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NKTR
NKTR
TACT
TACT
Q4 25
$21.8M
$11.5M
Q3 25
$11.8M
$13.2M
Q2 25
$11.2M
$13.8M
Q1 25
$10.5M
$13.1M
Q4 24
$29.2M
$10.2M
Q3 24
$24.1M
$10.9M
Q2 24
$23.5M
$11.6M
Q1 24
$21.6M
$10.7M
Net Profit
NKTR
NKTR
TACT
TACT
Q4 25
$-36.1M
Q3 25
$-35.5M
$15.0K
Q2 25
$-41.6M
$-143.0K
Q1 25
$-50.9M
$19.0K
Q4 24
$7.3M
Q3 24
$-37.1M
$-551.0K
Q2 24
$-52.4M
$-319.0K
Q1 24
$-36.8M
$-1.0M
Gross Margin
NKTR
NKTR
TACT
TACT
Q4 25
47.6%
Q3 25
49.8%
Q2 25
48.2%
Q1 25
48.7%
Q4 24
72.7%
44.2%
Q3 24
81.6%
48.1%
Q2 24
58.5%
52.7%
Q1 24
60.6%
52.6%
Operating Margin
NKTR
NKTR
TACT
TACT
Q4 25
-126.9%
-10.1%
Q3 25
-268.6%
0.1%
Q2 25
-324.2%
-1.9%
Q1 25
-425.8%
-0.1%
Q4 24
49.2%
-10.3%
Q3 24
-142.4%
-7.7%
Q2 24
-211.9%
-3.8%
Q1 24
-163.7%
-12.2%
Net Margin
NKTR
NKTR
TACT
TACT
Q4 25
-165.4%
Q3 25
-301.3%
0.1%
Q2 25
-372.2%
-1.0%
Q1 25
-486.4%
0.1%
Q4 24
24.9%
Q3 24
-153.6%
-5.1%
Q2 24
-222.9%
-2.8%
Q1 24
-170.1%
-9.7%
EPS (diluted)
NKTR
NKTR
TACT
TACT
Q4 25
$-4.67
$-0.11
Q3 25
$-1.87
$0.00
Q2 25
$-2.95
$-0.01
Q1 25
$-0.24
$0.00
Q4 24
$-2.07
$-0.80
Q3 24
$-2.66
$-0.06
Q2 24
$-3.76
$-0.03
Q1 24
$-0.19
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NKTR
NKTR
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$15.1M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$89.8M
$31.1M
Total Assets
$280.4M
$44.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NKTR
NKTR
TACT
TACT
Q4 25
$15.1M
$20.4M
Q3 25
$41.0M
$20.0M
Q2 25
$43.0M
$17.7M
Q1 25
$38.9M
$14.2M
Q4 24
$44.3M
$14.4M
Q3 24
$30.1M
$11.3M
Q2 24
$27.9M
$11.1M
Q1 24
$48.6M
$10.6M
Stockholders' Equity
NKTR
NKTR
TACT
TACT
Q4 25
$89.8M
$31.1M
Q3 25
$85.1M
$31.8M
Q2 25
$-24.2M
$31.3M
Q1 25
$13.7M
$30.9M
Q4 24
$60.7M
$30.6M
Q3 24
$48.9M
$38.4M
Q2 24
$79.7M
$38.5M
Q1 24
$126.7M
$38.6M
Total Assets
NKTR
NKTR
TACT
TACT
Q4 25
$280.4M
$44.8M
Q3 25
$301.3M
$45.0M
Q2 25
$207.5M
$44.5M
Q1 25
$256.2M
$44.2M
Q4 24
$303.9M
$44.0M
Q3 24
$308.0M
$50.5M
Q2 24
$343.3M
$50.4M
Q1 24
$396.0M
$51.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NKTR
NKTR
TACT
TACT
Operating Cash FlowLast quarter
$-65.0M
$609.0K
Free Cash FlowOCF − Capex
$-65.0M
$589.0K
FCF MarginFCF / Revenue
-298.0%
5.1%
Capex IntensityCapex / Revenue
0.1%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-208.7M
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NKTR
NKTR
TACT
TACT
Q4 25
$-65.0M
$609.0K
Q3 25
$-48.8M
$3.6M
Q2 25
$-45.7M
$3.6M
Q1 25
$-49.1M
$-161.0K
Q4 24
$-46.2M
$2.4M
Q3 24
$-43.9M
$327.0K
Q2 24
$-37.7M
$636.0K
Q1 24
$-47.9M
$-1.5M
Free Cash Flow
NKTR
NKTR
TACT
TACT
Q4 25
$-65.0M
$589.0K
Q3 25
$-48.9M
$3.6M
Q2 25
$-45.8M
$3.6M
Q1 25
$-49.1M
$-171.0K
Q4 24
$-46.6M
$2.4M
Q3 24
$-44.6M
$259.0K
Q2 24
$-37.9M
$499.0K
Q1 24
$-48.0M
$-1.6M
FCF Margin
NKTR
NKTR
TACT
TACT
Q4 25
-298.0%
5.1%
Q3 25
-414.5%
27.1%
Q2 25
-409.6%
25.9%
Q1 25
-469.0%
-1.3%
Q4 24
-159.9%
23.2%
Q3 24
-184.9%
2.4%
Q2 24
-161.3%
4.3%
Q1 24
-222.0%
-14.9%
Capex Intensity
NKTR
NKTR
TACT
TACT
Q4 25
0.1%
0.2%
Q3 25
1.0%
0.5%
Q2 25
0.3%
0.1%
Q1 25
0.0%
0.1%
Q4 24
1.6%
0.1%
Q3 24
2.8%
0.6%
Q2 24
0.8%
1.2%
Q1 24
0.7%
1.0%
Cash Conversion
NKTR
NKTR
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
-6.36×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons